|IP||0.2-1 μL/mg of lysate|
**********Please Note: Optimal concentrations/dilutions should be determined by the end user.**********
Anti-LAMP1 rabbit monoclonal antibody at 1:500 dilution
Lane A: Jurkat Whole Cell LysateLysates/proteins at 30 μg per lane.
Goat Anti-Rabbit IgG H&L (Dylight800) at 1/10000 dilution.Developed using the Odyssey technique.
Performed under reducing conditions.Predicted band size:120 kDa
Observed band size:120 kDa
LAMP1 was immunoprecipitated using:
Lane A:0.5 mg Jurkat Whole Cell Lysate1 µL anti-LAMP1 rabbit monoclonal antibody and 15 μl of 50 % Protein G agarose.Primary antibody:
Anti-LAMP1 rabbit monoclonal antibody,at 1:500 dilutionSecondary antibody:
Dylight 800-labeled antibody to rabbit IgG (H+L), at 1:5000 dilutionDeveloped using the odssey technique.
Performed under reducing conditions.Predicted band size: 45 kDa
Observed band size: 113 kDa
Lysosome-associated membrane glycoprotein 1, also known as CD107 antigen-like family member A, CD107a, and LAMP1, is a single-pass type I membrane protein which belongs to the LAMP family. CD107a is expressed largely in the endosome-lysosome membranes of cells, but is also found on the plasma membrane (1-2% of total LAMP1). LAMP1 has been implicated in a variety of cellular functions, including cancer metastasis. It has been proposed LAMP1 serves as a therapeutic agent for some cancers, as well as a marker for lysosomal storage disorders and different cell types such as cytotoxic T cells. LAMP2, also known as CD107b, may also play a role in tumor cell metastasis and functions in the protection, maintenance, and adhesion of the lysosome. Cell surface LAMP1 and LAMP2 have been shown to promote adhesion of human peripheral blood mononuclear cells (PBMC) to vascular endothelium, therefore they are possibly involved in the adhesion of PBMCs to the site of inflammation. LAMP-1 is a glycoprotein highly expressed in lysosomal membranes. The present study was initiated to test LAMP-1 mRNA and protein levels in post mortem frontal cortex (area 8) of Alzheimer's disease (AD) stages I-IIA/B and stages V-VIC of Braak and Braak, compared with age-matched controls. LAMP-1 occurred in microglia and multinucleated giant cells in one AD case in whom amyloid burden was cleared following betaA-peptide immunization. In addition, LAMP-1 has been suggested to be a cell surface receptor for a specific amelogenin isoform, leucine-rich amelogenin peptide or LRAP. LAMP-1 can serve as a cell surface binding site for amelogenin on dental follicle cells and cementoblasts.
|Product Description||Host||Clonality||Application||Catalog# (PDF)|
|Anti-LAMP1 Antibody (APC)||Rabbit||Monoclonal||FCM||11215-R107-A|
|Anti-LAMP1 Antibody (PE)||Mouse||Monoclonal||FCM||11215-MM07-P|
|Anti-LAMP1 Antibody (PE)||Rabbit||Monoclonal||FCM||11215-R107-P|
|Anti-LAMP1 Antibody (FITC)||Mouse||Monoclonal||FCM||11215-MM07-F|
|Anti-LAMP1 Antibody (FITC)||Rabbit||Monoclonal||FCM||11215-R107-F|